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Abstract 
Background: Acute radiation enteritis is a common adverse effect related to radiotherapy (RT). Glutamine is an 
immune modulator and antioxidant amino acid that can exert a protective role in patients receiving abdominal or 
pelvic radiation. The aim of this study was to test if glutamine prevents radiation enteritis during RT. Materials and 
Methods: Double-blind, randomized, controlled trial including 69 patients who needed RT because of pelvic or 
abdominal malignancies and received glutamine (30 g/d) or placebo (casein, 30 g/d). Enteritis was evaluated 
according to the Radiation Therapy Oncology Group scale, intestinal inflammation using fecal calprotectin, and gut 
integrity with citrulline. The incidence of enteritis was analyzed by Kaplan-Meier curves, and the hazard ratio (HR) 
was calculated using Cox regression. Results: Patients were predominantly male (65.2%), with an average (SD) age 
of 66.6 (9.9) years, with urologic (44.9%), rectal (24.6%), or gynecological cancer (23.1%). More patients developed 
enteritis with glutamine than with the placebo (55.9% vs 22.0%; P = .002), with an HR of 1.59 (95% confidence 
interval, 0.62–4.05). There were no differences in final calprotectin levels (glutamine, 57.9 [85.8] mg/kg vs placebo, 
54.0 [57.7] mg/kg; P = .182) or the number of patients with values >50 mg/kg (glutamine, 58.1% vs placebo, 54.6%; 
P = .777). Final citrulline levels were similar between groups (glutamine, 26.31 [10.29] mmol/L vs placebo, 27.69 
[12.31] mmol/L; P = .639), without differences in the number of patients with <20 mmol/L (glutamine, 24.1% vs 
placebo, 25.0%; P = .938). Citrulline concentration was reduced during RT with placebo but remained unchanged 
with glutamine. Conclusion: Glutamine does not prevent the development of enteritis during RT.  
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Clinical Relevancy Statement 
Toxicity related to cancer therapy negatively influences quality of life of patients, compromises the 
completion of treatments, and is associated with higher expenses. Glutamine may have a protective effect 
in patients receiving radiation therapy, but few randomized controlled trials have been published testing 
this hypothesis. The findings of this study do not support the use of glutamine in the prevention of acute 
radiation enteritis and could even promote the development of intestinal toxicity.  
Introduction 
Despite the development of new therapies for the treatment of cancer, approximately half of oncology 
patients receive radiotherapy (RT), including those with abdominal and pelvic neoplasias. Nevertheless, 
the therapeutic use of ionizing radiation is limited by its adverse effects. Acute radiation-related toxicity 
depends on the suppression of cell replication in organs of rapid cell turnover (eg, bone marrow), 
typically develops during its administration, and is resolved within 1–2 months. Acute radiation enteritis 
(ARE) represents the toxicity that develops in the small intestine during RT. ARE involves different 
mechanisms, including the depletion of stem cells in the crypts of Lieberkühn, endothelial dysfunction, 
alterations in intestinal contractility, and changes that radiation induces on intestinal microbiota.
1
 These 
alterations contribute to a decrease in the absorptive surface of the mucosa and to an increase in the speed 
of intestinal transit, resulting in diarrhea, abdominal pain, anorexia, nausea, and vomiting.  
Ionizing radiation causes cellular damage by means of several mechanisms, including oxidative stress 
(OS), inflammation, genetic damage, apoptosis, changes in the cellular membrane, and vascular 
alterations. Acute exposure to radiation generates free radicals, such as the superoxide radical. Human 
cells possess various defenses against these reactive molecules, including enzymes (eg, glutathione 
peroxidase), cofactors (eg, glutathione), and nutrients (eg, glutamine). Both cells and tissues have a 
limited ability to enhance the antioxidant system in response to an oxidant factor such as radiation, and 
when it is overwhelmed by reactive species and free radicals, molecular damage is induced.
2
 In addition 
to oxidative reactions, radiation stimulates the generation of nuclear factor κB (NF-κB), interleukins, and 
tumor necrosis factor–α (TNF-α). The gut, liver, and brain have a high expression of the former, which is 
only moderately produced in the lung, heart, spleen, kidney, and testes.
3
 
Glutamine is the most abundant amino acid in the body.
4
 Several functions of glutamine may play a 
role in the protection of the healthy gut during RT. First, glutamine contributes to intestinal trophism, as 
the small intestine is the principal consumer of glutamine in the body. Second, glutamine is the precursor 
of glutathione, a key molecule in the antioxidant chain. Third, glutamine modulates the inflammatory 
response in different immune cells and regulates cytokine production. And finally, glutamine protects 
cells from various insults by the production of heat shock proteins and also influences apoptosis.
5
 Few 
studies have assessed if glutamine prevents ARE, and the results have been disparate.
6⇓-8 The aim of this 
study was to test if oral glutamine prevents the development of acute enteritis, protects the intestinal 
mucosa, and limits gut inflammation in patients receiving either abdominal or pelvic radiation therapy.  
Patients and Methods 
A randomized, controlled, double-blind study was designed to compare the effectiveness of glutamine 
vs placebo in the prevention of ARE. The study was evaluated by the local Research Ethics Committee, 
which confirmed that the study conformed to the ethical and legal standards required for biomedical 
research according to the Declaration of Helsinki. The study was registered in Clinical Trials with the 
number NCT00828399.  
Patients 
Patients >18 years for whom RT of the abdominal/pelvic cavity was planned because of a neoplasm in 
that location, regardless of other cancer treatments (surgery, chemotherapy, brachytherapy), were 
considered suitable for the trial. All patients were recruited by the research group in the Complejo 
Asistencial Universitario de León, where the trial took place. Exclusion criteria included life expectancy 
<1 year, intestinal failure or short bowel syndrome of any etiology, relevant intestinal diseases 
(inflammatory bowel disease, celiac disease, Whipple disease), moderate or severe chronic kidney 
disease, or inability to receive oral medication or to understand the provided information. All patients 
received verbal and written information about the purpose and methodology of the study and were 
included after signing the informed consent document. Randomization, which took place at the time of 
recruitment, was conducted by the investigator who recruited the patients in a 1:1 ratio to each group by 
generating a list of random numbers with the software Epidat 3.1 (Organización Panamericanade la 
Salud, Washington D.C., USA; Figure 1). Patients, the principal investigator, and co-investigators were 
blinded for treatment assignation and outcomes until the end of the trial, and the blind was broken after 
the completion of statistical analysis.  
  
 
 
 
Figure 1. Flowchart of the study. The recruitment included 69 of the 88 patients initially invited to participate, and all the recruited 
patients were randomized and included in the intention-to-treat analysis. One patient in the glutamine group withdrew on the last 
visit of the study due to an underlying disease different from that indicated for radiotherapy (RT).  
Intervention 
The treatment group received 30 g/d of oral glutamine (Glutamina NM; Nutrición Médica, Madrid, 
Spain), and the placebo group received 30 g/d of pure whole casein (Proteína NM; Nutrición Médica). 
This dose of glutamine was selected following previous studies that administered oral glutamine for RT, 
chemotherapy, or bone marrow transplantation. Both substances were supplied as a powder for 
dissolution without flavor, contained in nonlabeled sachets of 10 g of product. Investigators 
recommended the consumption of 3 sachets/d, from 3 days before starting RT and to the completion of it. 
Each sachet was dissolved in 200 mL of water, and the solution was drunk after a meal. Both glutamine 
and placebo had similar color, taste, and texture before and after dissolution. Patients with mild chronic 
kidney disease were informed by a dietitian to adjust their dietary protein intake, taking into account the 
added contribution of the substance administered during the study.  
Acute Radiation Enteritis Assessment 
Patients were evaluated at 3 different time points during the study: before RT (recruitment), in the 
middle of the RT period, and after finishing RT. They were asked about the number and characteristics of 
stools at each visit. Intestinal toxicity was classified according to the criteria of the Radiation Therapy 
Oncology Group (RTOG): grade 0 (no diarrhea), grade 1 (increase of 2–3 stools/d), grade 2 (increase of 
4–6 stools/d, nocturnal stools, mild cramping), grade 3 (increase of 7–9 stools/d, fecal incontinence, 
severe cramping), and grade 4 (increase >10 stools/d, bloody diarrhea, parenteral nutrition).  
  
Nutrition Assessment 
All patients were evaluated at each visit using the Subjective Global Assessment (SGA). 
Anthropometry included the measurement of height and body weight, dynamometry (Smedley’s Dynamo 
Meter; YOII/ Tsutsumi /TTM, Tokyo, Japan), and the determination of fat-free mass (FFM) and fat mass 
(FM) by bioelectrical impedance (Tanita Body Composition Analyzer TBF-300; Tanita, Arlington 
Heights, IL). From these results, the fat-free mass index was calculated: FFMI = fat-free mass (kg)/height 
(m)
2
. Dietary intake was assessed using 3-day dietary records at each visit, with the support of a dietitian, 
who analyzed the data using Dietsource 2.0 (Novartis Consumer Health-Cath Soft, 1997–2003; Novartis, 
East Hanover, NJ).  
Analytical Methods 
Blood samples were taken at each visit for blood cell counts, biochemistry (glucose, serum urea 
nitrogen, creatinine, ions, alanine aminotransferase, aspartate aminotransferase), nutrition biomarkers 
(serum albumin, prealbumin, retinol binding protein, and total cholesterol), and inflammatory parameters 
(C-reactive protein [CRP] and ferritin). Tumor markers (carcinoembryonic antigen [CEA] and prostate-
specific antigen [PSA]) were measured before and after RT. Villous functional mass was assessed using 
plasma citrulline. For this purpose, 0.5 mL of blood was obtained before and after RT, conserved in 
EDTA, and analyzed by high-performance liquid chromatography. A cutoff of 20 mmol/L was 
established for significant intestinal mucosal damage. Inflammation of the intestinal mucosa was 
determined by means of fecal calprotectin, by obtaining a stool sample before and after RT, which was 
analyzed by enzyme-linked immunosorbent assay. Values >50 mg/g were considered to indicate gut 
inflammation.
9
 
Statistical Analysis 
A total sample size of 70 patients (35 per group) was calculated to detect a difference of 30% in the 
incidence of ARE among groups with an accuracy of 5%, according to the results reported by Ramírez 
Vargas
10
 at the Congress of the European Society for Radiotherapy and Oncology in 2009. An intention-
to-treat analysis was performed. The normal distribution of quantitative variables was examined by the 
Kolmogorov-Smirnov test. Those with a normal distribution were summarized as the mean and standard 
deviation (SD) and compared with an unpaired Student t test. When more than 2 groups were compared, 
the analysis of variance test was used. Quantitative variables without a normal distribution were 
summarized by the median (Md) and interquartile range (IQR) and compared using the Mann-Whitney U 
test or the Friedman test when comparing more than 2 groups. Categorical variables were summarized as 
percentages and compared with the χ2 test. The comparison of the incidence of enteritis between 
treatment and placebo was performed using the Kaplan-Meier method, and survival curves were 
compared using the Mantel-Haenszel test. The hazard ratio (HR) was calculated using Cox regression. 
Multivariate analyses were performed using binary logistic and linear regression.  
Results 
Sixty-nine patients were recruited, of whom 34 were assigned to glutamine (GLN) and 35 to placebo 
(PLA). During follow-up, 1 patient in the former group dropped out the trial due to complications from an 
underlying disease. The characteristics of both groups are summarized in Table 1. Both treatment groups 
received the same dose of RT (GLN Md [IQR] = 51.0 [28.0] Gy; PLA Md [IQR] = 50.4 [29.0] Gy; P = 
.636), with a fractionation dose of 1.8 (IQR = 0.1) Gy/session for patients receiving GLN and 1.9 (IQR = 
0.1) Gy/session for those who received PLA (P = .745). The received dose of GLN was 0.4 (0.1) g/kg/d, 
with a minimum dose of 0.3 g/kg/d and a maximum of 0.6 g/kg/d.  
  
 
 
Acute Radiation Enteritis 
More patients developed ARE with GLN than with PLA (55.9% vs 22.0%; P = .002), with an HR of 
developing enteritis among the former group of 1.59 (95% confidence interval [CI], 0.62–4.05). The 
median cumulative dose of radiation to develop diarrhea was 21.6 Gy for GLN and 25 Gy for PLA, but 
there was no significant difference between the survival curves, as shown in Figure 2. No differences 
were found in the number of stools per day between GLN and PLA at visit 1 (Md [IQR] = 1.0 [1.0] vs 1.0 
[0.8]; P = .918) and visit 3 (Md [IQR] = 2.0 [2.0] vs 2.0 [2.0]; P = .513). At visit 2, stool frequency was 
higher with GLN (Md [IQR] = 2.0 [3.5] vs 1.0 [0.8]; P = .037). In the middle of RT, GLN was associated 
with more patients with soft or liquid stools (51.5% vs 18.8%; P = .011), but this difference was not 
found at either visit 1 or visit 3. The grades of acute enteritis according to the RTOG criteria are shown in 
Table 2. Loperamide was required in 12.1% of patients with GLN and 5.7% with PLA (P = .352). Two 
patients in the placebo group and none in the glutamine group interrupted RT because of diarrhea.  
  
 
 
 
Figure 2. Appearance of acute radiation enteritis according to the intervention. 
Kaplan-Meier curves represent the new cases of acute radiation enteritis during 
the radiotherapy. The vertical axis represents the cumulative incidence of 
intestinal toxicity. The continuous line represents patients receiving glutamine 
and the dashed line those receiving placebo.  
 
 
Among patients with urological neoplasms, ARE was more frequent with GLN than with PLA (50.0% 
vs 6.7%; P = .008), but there were no significant differences in those with gynecological (75.0% vs 
37.5%; P = .131) or rectal cancer (71.4% vs 30.0%; P = .092). After adjusting for different variables (sex, 
age, chemotherapy, brachytherapy, type of cancer, intervention, body mass index [BMI]) with 
multivariate analysis, only 3 factors were independently associated with ARE: treatment with glutamine 
(odds ratio [OR], 7.4; 95% CI, 1.8–30.9), gynecological cancer (OR, 20.0; 95% CI, 2.8–143.9), and rectal 
neoplasm (OR, 7.9; 95% CI, 1.5–41.5). There were no differences in ARE depending on the dose of 
glutamine per kilogram of weight.  
  
Citrulline 
Before RT, both groups had similar citrulline concentrations (GLN, 30.0 [16.5] mmol/L vs PLA, 37.4 
[23.4] mmol/L; P = .172), and there was no difference at the end of study (GLN, 26.31 [10.29] mmol/L 
vs PLA, 27.69 [12.31] mmol/L; P = .639). When the overall group of patients was analyzed, PLA was 
associated with a significant reduction of citrulline compared with baseline (P = .040), but it remained 
unchanged in the glutamine group (P = .326). Patients treated with glutamine who developed ARE tended 
to present lower concentrations of citrulline than those without diarrhea (Figure 3), and there were no 
differences in PLA. A similar percentage of patients in both groups presented with a citrulline level <20 
mmol/L (GLN, 24.14% vs PLA, 25.0%; P = .938).  
 
 
 
Figure 3. Plasma citrulline concentration after radiotherapy, according to the appearance of acute radiation enteritis. The central line 
of the box plot represents the median and the lower and upper borders the first and third quartiles, respectively. Patients receiving 
glutamine who developed intestinal toxicity tended to present with reduced concentrations of citrulline, but this amino acid 
remained clearly unchanged among those receiving placebo.  
Calprotectin 
The number of patients with elevated calprotectin before RT differed significantly depending on the 
underlying disease: rectal cancer (69.2%), prostate cancer (52.0%), and gynecological cancer (7.7%) (P = 
.019). There were no differences in calprotectin concentrations between groups either before (GLN Md 
[IQR] = 55.0 [134.6] mg/kg, PLA Md [IQR] = 43.4 [105.4] mg/kg; P = .949) or after RT (GLN Md [IQR] 
= 57.9 [85.8] mg/kg, PLA Md [IQR] = 54.0 [57.0] mg/kg; P = .182). However, there was an increase in 
the number of patients with a detectable concentration of fecal calprotectin in GLN during RT (visit 1, 
55.2%; visit 3, 83.9%; P = .032) that was not observed in PLA (visit 1, 69.0%; visit 3, 66.7%; P > .05). In 
the overall group, there was no difference in the number of patients with calprotectin >50 mg/kg after RT 
(GLN, 58.1%; PLA, 54.6%; P = .777), but when only the patients who developed ARE were analyzed, 
high calprotectin concentrations were more frequently found in GLN than in PLA (70.0% vs 16.7%; P = 
.022).  
Systemic Inflammation 
Initial ferritin concentrations were significantly higher among patients with prostate tumors than in 
patients with other neoplasms (318.7 [435.6] ng/mL vs 98.1 [166.8] ng/mL; P < .001), and this difference 
persisted at visit 2 (337.7 [452.5] ng/mL vs 110.1 [166.1] ng/mL; P < .001) and at visit 3 (318.1 [432.7] 
ng/mL vs 121.0 [432.7] ng/mL; P = .001). This difference remained after adjusting for other variables 
such as age, sex, body composition, nutrition status, and treatment with chemotherapy or surgery. There 
were no differences in CRP levels among the different neoplasms at any study visit. In both groups, there 
was a significant increase in ferritin values at the end of the RT, but not in the concentration of CRP 
(Figure 4). There were no differences between the 2 groups in the values of these parameters at any visit.  
 
 
 
Figure 4. Evolution of systemic inflammatory parameters. Box plot represents the evolution of inflammatory parameters during the 
follow-up. Ferritin concentrations rose in the both arms of the study during the radiotherapy, but C-reactive protein did not change. 
There were no differences between the arms of the trial.  
Nutrition Status 
According to SGA, 10 cases (14.4%) of moderate malnutrition were found before RT, most of them 
among patients with rectal (4/10) and gynecological tumors (3/10). During follow-up, 8.8% of patients 
with glutamine and 5.7% with placebo developed malnutrition (P = .618). Both groups maintained a 
stable weight, BMI, FM, and FFMI during follow-up, and the percentage of patients with significant 
weight loss (>5%) was low in both groups: 3.0% in GLN and 5.7% in PLA (P = .590). The evolution of 
nutrition parameters and macronutrient intake is summarized in Table 3. Both intervention groups 
consumed a similar amount of micronutrients with antioxidant function during RT (vitamins A, E, and C; 
selenium; and zinc; data not shown).  
 
Adverse Effects 
Four patients with placebo had vomiting that forced them to stop treatment, but glutamine was well 
tolerated in all patients. Compliance was assessed counting the remaining envelopes after the finish of 
radiotherapy, and all patients except those not tolerating the placebo correctly took the provided 
treatment. The glomerular filtration rate was stable in both groups during follow-up. Patients did not have 
high PSA values at the end of RT, and the same percentage had high CEA concentrations (GLN, 14.3% 
vs PLA, 12.5%; P = .919). Other adverse effects are summarized in Table 4.  
 
 
Discussion 
Some nutrients, including glutamine, have been proposed for modifying the therapeutic window by 
enhancing the cytotoxic action on the tumor or by preserving healthy tissue. Diarrhea is one of the most 
common side effects of cancer therapy, affecting up to 50% of patients with chemotherapy and 30% with 
pelvic RT. In this context, a randomized, controlled, double-blind trial was designed to test the 
effectiveness of glutamine in the prevention of radiation enteritis. The results show that glutamine was 
independently associated with the development of ARE.  
Only 2 studies suggesting some benefit of glutamine during pelvic RT have been published and only 
in abstract form. The study by Richards et al
6
 included patients with prostate cancer who received either 
glutamine (21 g/d) or placebo. The former was associated with less tissue damage in the rectum, but there 
was no difference in stool frequency. In the second study, which included mostly patients with 
gynecological tumors, glutamine (30 g/d) was associated with a lower incidence of ARE, but this study 
was neither blinded nor controlled.
9
 A third study included a single cohort of patients with gynecological 
or rectal cancer receiving 30 g of oral glutamine, in which ARE occurred in 73% of patients, a percentage 
similar to that observed in patients with the same tumors who received glutamine in our trial.
11
 Only 2 
RCTs have been fully published. The study by Kozelsky et al
7
 included patients with pelvic cancer, and 
there were no differences in the development of acute toxicity. The second RCT included patients with 
rectal cancer who received glutamine (30 g) or placebo. In the glutamine group, more patients developed 
ARE than with placebo, although this difference was not significant.
8
 Among the weaknesses of this 
study was that an intention-to-treat analysis was not performed. The sample size was smaller than that of 
our trial, and this may have influenced the statistical significance.  
Arginine supplementation in rats receiving abdominal RT has been related to greater colonic damage, 
possibly caused by nitric oxide (NO) overproduction.
12
 NO plays a dual role in the gut by promoting the 
maintenance of barrier function and compromising the viability of intestinal cells when generated in 
excessive amounts. The addition of glutamine to intestinal cells in vitro does not favor the formation of 
NO, but glutamine could act indirectly by the glutamine-citrulline-arginine metabolic pathway. 
Macrophages cultured in glutamine-enriched medium and stimulated with lipopolysaccharide are able to 
produce NO even in the absence of arginine, suggesting that a stimulus may be necessary for glutamine to 
enhance the production of NO.
13
 This mechanism may explain why glutamine-related adverse effects 
have not been reported when radiation therapy is administered in body areas (head and neck, esophagus) 
where there is no local production of citrulline, which can serve as a substrate for NO synthesis. In 
addition, NO may play a dual role as a radiosensitizer or radioprotector. The former is mediated through 
its antioxidant properties when it is generated in low concentrations and the latter in combination with the 
superoxide anion.
14
 These actions of NO are dose dependent, and it is necessary to achieve a minimum 
threshold to produce toxicity. Glutamine in this context may be a substrate that would favor excessive 
production by the mechanisms described above, explaining why the study providing 21 g of the amino 
acid had no adverse effects.
6,8
 In addition, glutamine might behave at certain doses as a pro-oxidant agent. 
Glutamine at doses of 0.15 g/kg, administered to women with breast cancer treated with chemotherapy, 
failed to increase glutathione levels in healthy breast tissue and plasma.
15
 Shinozaki et al
16
 observed in 
rats with chemically induced colitis that a diet containing 12% glutamine was associated with lower 
intestinal inflammation than a diet free of this amino acid, but a diet that provided 24% glutamine 
produced more inflammation.  
The concentration of calprotectin increases as a result of treatment with RT. In this study, there was an 
increase in the number of patients who had detectable levels of calprotectin in the glutamine group, and 
among patients who developed enteritis, the frequency of elevated calprotectin was higher in those 
assigned to glutamine. These findings suggest the development of intestinal inflammation associated with 
glutamine treatment. The final concentrations of calprotectin did not differ between groups. It has been 
described that calprotectin reaches a maximum value after 5 weeks of RT and subsequently decreases 
gradually. So, it is possible that when the final sample was obtained, the calprotectin concentrations were 
already in decline or that liquid stools could have diluted the concentrations of calprotectin. Rectal and 
prostate cancers were more frequently associated with elevated calprotectin before RT. It has been 
reported that carcinomas and colon adenomas express calprotectin. However, it is striking that more than 
half of patients with prostate cancer showed intestinal inflammation, as well as higher ferritin levels. The 
patients with prostate cancer enrolled in this study were undergoing androgen deprivation therapy with 
GnRH analogues. In mice, castration has been associated with increased intestinal inflammatory response 
secondary to the administration of radiation.
17
 Human data on the immune status of men with 
hypogonadism are scarce. A case-control study reported an exacerbation of the specific immune response 
after different injuries, inversely proportional to the concentrations of circulating testosterone.
18
 
Systemic inflammatory response was similar in both arms. In a study by Kozjek et al,
8
 a significant 
elevation of interleukin-6 was associated with glutamine. The role of glutamine in the regulation of 
cytokine production seems to depend on factors such as dose as well as the noxious stimulus. In the 
healthy human gut, glutamine administration decreases the production of proinflammatory cytokines.
19
 
Nevertheless, the administration of glutamine above physiological concentrations can directly stimulate 
the release of TNF-α and also increases the production of NF-κB and interleukins in macrophages 
stimulated by lipopolysaccharide.
20
 
Citrulline values decrease with the administration of radiation proportionally to the dose received by 
the intestine, especially from the third week of treatment.
21
 In this trial, the concentration of citrulline 
significantly decreased in the placebo group after radiation therapy but remained stable in patients 
receiving glutamine. These results could indicate that there was a better conservation of villous mass with 
the administration of glutamine, although these patients presented with ARE and intestinal inflammation 
more frequently. However, some studies have shown a poor correlation between the clinical severity of 
ARE and citrulline.
22
 
The main strength of the present trial includes its methodology, as randomized, controlled, double-
blind trials on the use of glutamine in abdominal/pelvic radiation therapy are scarce. However, some 
limitations should be noted. First, this study was performed in a single center, making it difficult to 
generalize the results given differences in the population or RT techniques. Second, citrulline and 
calprotectin could not be analyzed in the middle of treatment, when ARE was more frequent and 
clinically evident. Third, specific markers of inflammation (eg, TNF-α, interleukins) or oxidative stress 
could not be evaluated. Finally, a larger sample size would have added potency to the study.  
In conclusion, the administration of oral glutamine during abdominal or pelvic RT was not useful for 
the prevention of acute enteritis and could have favored the development of diarrhea. This effect may be 
specifically related to intestinal exposure to radiation, as it has not been observed in other kinds of 
diarrhea or in RT over other corporal areas, as well as to the administered dose (30 g). The mechanisms 
explaining the relationship between gut inflammation, glutamine, and radiation are not clear and should 
be researched in new studies.  
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